(Q40329667)

English

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial

scientific article published on 6 April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: An open, randomized controlled trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Timo Vesikari

1

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Aino Karvonen

2

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Veronique Bianco

3

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Marie Van der Wielen

4

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Jacqueline Miller

5

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

language of work or name

0 references

publication date

6 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

29

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

25

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

4274-4284

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

A surveillance network for meningococcal disease in Europe.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Global epidemiology of meningococcal disease.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Meningococcal serogroup B infections: a search for a broadly protective vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Meningococcal polysaccharide-protein conjugate vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Outbreak of serogroup W135 meningococcal disease after the Hajj pilgrimage, Europe, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Effectiveness of a Mass Immunization Campaign Against Serogroup C Meningococcal Disease in Quebec

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Planning, registration, and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Protection from routine vaccination at the age of 14 months with meningococcal serogroup C conjugate vaccine in the Netherlands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15–25 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Increasing coverage and efficiency of measles, mumps, and rubella vaccine and introducing universal varicella vaccination in Europe: a role for the combined vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Use of a new combined vaccine in pediatric practices

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Do too many shots due lead to missed vaccination opportunities? Does it matter?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Meningococcal surrogates of protection--serum bactericidal antibody activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Human immunity to the meningococcus. I. The role of humoral antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Standardisation and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A and C vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

A combined measles, mumps, rubella and varicella vaccine (Priorix-Tetra): immunogenicity and safety profile.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Prevention of meningococcal serogroup C disease by NeisVac-C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vacc

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Reactogenicity and immunogenicity of combined Haemophilus influenzae type b-meningococcal serogroup C conjugate vaccine booster dose coadministered with measles, mumps, and rubella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Impact of meningococcal C conjugate vaccine use in Australia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.03.043

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.03.043

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40329667&oldid=1895501865"